Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 23 of the 62 sources its claims cite were checked for support.

Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation

Open access

Abstract

Preclinical studies demonstrate that rapid acting antidepressants, including ketamine require stimulation of mTORC1 signaling. This pathway is regulated by neuronal activity, endocrine and metabolic signals, notably the amino acid leucine, which activates mTORC1 signaling via binding to the upstream regulator sestrin. Here, we examined the antidepressant actions of NV-5138, a novel highly selective small molecule modulator of sestrin that penetrates the blood brain barrier. The results demonstrate that a single dose of NV-5138 produced rapid and long-lasting antidepressant effects, and rapidly reversed anhedonia caused by chronic stress exposure. The antidepressant actions of NV-5138 required BDNF release as the behavioral responses are blocked by infusion of a BDNF neutralizing antibody into the medial prefrontal cortex (mPFC) or in mice with a knock-in of a BDNF polymorphism that blocks activity dependent BDNF release. NV-5138 administration also rapidly increased synapse number and function in the mPFC, and reversed the synaptic deficits caused by chronic stress. Together, the results demonstrate that NV-5138 produced rapid synaptic and antidepressant behavioral responses via activation of the mTORC1 pathway and BDNF signaling, indicating that pharmacological modulation of sestrin is a novel approach for development of rapid acting antidepressants.

Overview

CoChat Summary

TL;DR

NV-5138, a brain-penetrant sestrin modulator, produced rapid and long-lasting antidepressant-like behavioral effects and reversed chronic stress–induced synaptic deficits in rodents. These effects required mTORC1 signaling and BDNF and were accompanied by increased synapse number and function in the medial prefrontal cortex.

Key findings

  • A single oral dose of NV-5138 at 160 mg/kg, but not 40 or 80 mg/kg, significantly reduced immobility in the FST and latency to feed in the NSFT; leucine (160 mg/kg) had no effect.
  • Single-dose NV-5138 and ketamine (10 mg/kg) produced antidepressant-like effects lasting up to 7 days in the FST, while repeated low-dose NV-5138 (80 mg/kg daily for 7 days) also significantly reduced immobility and latency to feed.
  • NV-5138 rapidly reversed chronic unpredictable stress–induced decreases in sucrose preference and increased NSFT latency, and reversed CUS-induced reductions in mPFC GluR1 and PSD95.
  • The behavioral actions of NV-5138 were blocked by intra-mPFC rapamycin or BDNF-neutralizing antibody and were absent in BDNF Val/Met and Met/Met knockin mice; NV-5138 also increased hypocretin-induced EPSC frequency, spine density, and synaptic proteins in mPFC.

Methods

  • Male Sprague-Dawley rats (250–260 g; 120–140 g for CUS) and BDNF Val66Met knockin mice (8–12 weeks) were used; NV-5138 was given orally, ketamine intraperitoneally, and rapamycin, BDNF nAb, or IgG were infused into the mPFC.
  • Behavioral assays included FST, NSFT, FUST, locomotor activity, home-cage feeding, and sucrose preference; CUS consisted of 21 days of variable stressors (13 stressors, 2 per day).
  • Mechanistic measures included Western blots of synaptosomal PFC proteins, whole-cell patch recordings of layer V pyramidal neurons, and confocal spine analysis; data were analyzed with ANOVA/Tukey tests or Student’s t tests, with significance at P ≤ 0.05.

Limitations

  • The authors state that the CUS conclusion is tempered because they did not test the influence of NV-5138 on mTORC1 signaling in CUS-exposed rats.
  • The authors note that NBQX pretreatment did not block the FST effect and only partially, nonsignificantly blocked the NSFT effect, but state that higher or additional NBQX doses could reveal an AMPA receptor requirement.
  • The authors state that further studies are needed to assess side effects in rodents and primates, including whether mTORC1 activation could influence tumor growth; the text also makes evident that the findings are preclinical and most behavioral studies used male rats.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci126859

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

11 Valid · 0 Not valid · 21 Not checked · 75 Own results and interpretations

59 more claims · 2 with their cited sources checked

Create a free account to see all 107 claims and to verify the 39 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 20

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 50 references

Research works printed but not linked: 2

  1. 10.1002/(sici)1097-4644(20000501)77:2 · doi:10.1002/(sici)1097-4644(20000501)77:2
  2. 10.1146/annurev-med-053013-062946 · DOI · Paper page

Cited by

See all 88

Metadata

Authors
Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S.
Affiliations
  • Sumitomo Dainippon Pharma (Japan) (JP)
  • Yale University (US)
Corresponding author
Duman, Ronald S.
Venue
Journal of Clinical Investigation
Published
2019-05-20
Volume
129
Issue
6
Pages
2542-2554
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2936807256
Cited by
88
References
50
Citations by year
2026: 7 · 2025: 14 · 2024: 7 · 2023: 8 · 2022: 18 · 2021: 16 · 2020: 14 · 2019: 4
FWCI
8.05
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
NIMH, Navitor Pharmaceuticals Inc. (MH093897,MH105910)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
sestrins, mTORC1 signaling, rapid-acting antidepressants, antidepressant effects, brain-derived neurotrophic factor, chronic stress, anhedonia, medial prefrontal cortex, synapse number, synaptic deficits, leucine, blood-brain barrier, ketamine
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Animals, Antidepressive Agents, Behavior, Animal, Heat-Shock Proteins, Male, Synaptic Transmission, Rats, Sprague-Dawley, Mice, Knockout, Brain-Derived Neurotrophic Factor, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. https://app.cochat.ai/papers/10.1172/jci126859
The paper
Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S. (2019). Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. Journal of Clinical Investigation. https://doi.org/10.1172/jci126859

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.